Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience.

"We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuously improve the outcomes and experiences of patients suffering from foot and ankle conditions. It's a great experience for our team to share that progress each year at ACFAS."

Attendees will have the opportunity to explore some of P28's latest advancements, including:

• SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠
  • Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​.
  • Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion of surgical plans into patient-specific guides.
  • More information on SMART28℠ Advanced Technologies and the SMART Bun-Yo-Matic℠ can be found at https://smart.paragon28.com/.
• APEX 3D S™ Stemmed Tibial Implant and Right-Angle Drill
  • Expands the APEX 3D Total Ankle Replacement portfolio with a stemmed tibia implant. The stem is 12mm with the proximal 9mm being smooth to reduce stress shielding and the distal 3mm having a lattice structure for immediate fixation at time of implantation.
  • Instrumentation including a Right-Angle Drill and Linear Guide precisely prepares the tibia to receive the final APEX 3D S Stemmed Tibia Implant.
• Phantom® Fibula Nail System
  • Minimally invasive implant designed to help reduce soft tissue complications while providing fibula fracture stabilization​.
  • Features a proximal locking mechanism and syndesmotic fixation options for improved procedural outcomes.
• R3FLEX™ Stabilization System
  • Next-generation syndesmotic repair solution that allows surgeons to dynamically adjust and visualize tension during fixation​.
• FJ2000™ Power Console and Burr System
  • Sterile-packed, single-use power system designed for a wide range of foot and ankle procedures
• PRECISION® MIS Bunion System
  • Offers a minimally invasive solution for triplanar correction of bunions, enhancing surgical precision and patient recovery.

In addition to showcasing these innovations, Paragon 28 will be hosting two exclusive events at ACFAS:

• Paragon 28 Mobile Lab – Experience hands-on training with our latest technologies in a fully equipped mobile lab. [Link to Registration Page]
• Innovations in Foot and Ankle Dinner – Join us for an evening of discussion on the latest advancements in foot and ankle surgery, featuring industry-leading surgeons and Paragon 28 experts. [Link to Registration Page]

Visit us at Booth #824 during ACFAS to experience firsthand how our latest technologies are shaping the future of foot and ankle surgery. For more information about Paragon 28 and its comprehensive portfolio, visit www.paragon28.com.

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28's potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Paragon 28's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Paragon 28's business in general, see Paragon 28's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its Quarterly Reports on Form 10-Q, as updated periodically with its other lings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Disclaimer

Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250324829829/en/

Investor Contact

Matthew Brinckman

Senior Vice President, Strategy and Investor Relations

Phone: (720) 912-1332